Behind every cancer breakthrough is a journey - one that starts long before the clinic. At Evotec, we partner with biotech and pharma innovators to accelerate that journey, using our fully integrated drug discovery platform to move cancer therapies from concept to cure. Our approach is fast, flexible, and built for the complexity of oncology. Whether it’s identifying the right target or navigating translational challenges, we’re here to make your path to the clinic clearer - and faster. Discover more: https://hubs.ly/Q03x0NY60 #CancerTherapy #DrugDiscovery #OncologyInnovation
Info
Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.
- Website
-
http://www.evotec.com
Externer Link zu Evotec
- Branche
- Biotechnologieforschung
- Größe
- 5.001–10.000 Beschäftigte
- Hauptsitz
- Hamburg
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 1993
- Spezialgebiete
- CNS, Oncology, Pain, Neurosciences, Inflammation, Metabolic disease, Infection, Respiratory diseases, Drug-Discovery, CMC, IND enabling und Drug Development
Orte
Beschäftigte von Evotec
Updates
-
Evotec’s High Throughput Experimentation (HTE) platform enables the systematic exploration of chemical space by facilitating the parallel execution of multiple reaction conditions using minimal material. This approach supports both drug discovery and development by: • Generating high-density data sets to inform reaction optimization • Reducing experimental timelines through parallelization • Conserving valuable intermediates and reagents • Improving statistical robustness in identifying optimal conditions Our white paper presents detailed case studies- including Suzuki, Ullmann, and Buchwald couplings - demonstrating how HTE has been applied to address synthetic challenges, improve reproducibility, and support scale-up decisions. Access the full white paper to learn how Evotec integrates HTE into its workflows to support data-driven decision-making and accelerate the development of small molecule therapeutics: https://hubs.ly/Q03x2mzw0 #HighThroughputExperimentation #MedicinalChemistry #DrugDevelopment #ProcessOptimization #DrugDiscovery #DataDrivenScience #PharmaceuticalDevelopment
-
-
What if you could achieve more hits - and do it faster, smarter, and more cost-effectively? Evotec unveils how Iterative Screening, powered by machine learning and real-world screening data, is reshaping the way we approach drug discovery. Highlights: • Up to 5x more confirmed hits • Smaller, smarter batches guided by predictive models • Cell Painting features unlock deeper phenotypic insights • Ideal for complex, resource-intensive assays Explore the full poster and see how we're pushing the boundaries of what's possible in HTS: https://hubs.ly/Q03x0HgD0 #IterativeScreening #HighThroughputScreening #HTS
-
-
Speed Meets Specificity in Covalent Drug Discovery Evotec’s latest poster showcases how high-throughput mass spectrometry (HT-MS) is accelerating the discovery of site-specific covalent binders - even for the most challenging targets. What we achieved: • Screened 5,000 covalent compounds in just 1 day • Identified site-specific hits using peptide-centric RF/MS • Validated whole-protein binding with intact RF/MS • Delivered apparent EC50 and Kinact/KI data in record time This dual-screening strategy is a powerful toolkit for tackling cysteine-containing enzymes and beyond. Explore the full case study: https://hubs.ly/Q03x18460 #CovalentInhibitors #HTMS #DrugDiscovery #MassSpec
-
-
Live webinar happening this week! Join us for an exclusive BioSpace webinar featuring experts from Evotec and BioSpace as they unpack the biggest challenges facing R&D today - and share actionable strategies to overcome them. From smarter development models to tech-enabled efficiencies, this conversation will spotlight how the industry can adapt and thrive. Whether you're in biotech, pharma, or life sciences, this is a timely conversation you won’t want to miss. With live Q&A throughout the session - join the discussion. Register now: https://hubs.ly/Q03x0DZ00 #Pharma #Biotech #LifeSciences #DrugDevelopment #PharmaInnovation
-
-
Chronic inflammation and fibrosis remain some of the toughest challenges in medicine. At Evotec, we believe iPSC-derived macrophages could be the key to unlocking new, scalable treatments. Discover how our platform is reshaping the future of immunology and regenerative medicine. Dive into our latest article in Nature's Biopharma Dealmakers June issue: https://hubs.ly/Q03wqZNG0 #iPSC #CellTherapy
-
𝗣𝗿𝗲𝗱𝗶𝗰𝘁 𝗧𝗼𝘅𝗶𝗰𝗶𝘁𝘆 𝗕𝗲𝗳𝗼𝗿𝗲 𝗜𝘁 𝗛𝗮𝗽𝗽𝗲𝗻𝘀 — 𝘄𝗶𝘁𝗵 𝗖𝗲𝗹𝗹 𝗣𝗮𝗶𝗻𝘁𝗶𝗻𝗴 + 𝗔𝗜 Evotec showcases how Cell Painting, combined with advanced AI models, is redefining early safety/tox screening in drug discovery. Why it matters: • Detect 𝘀𝘂𝗯𝘁𝗹𝗲 𝗽𝗵𝗲𝗻𝗼𝘁𝘆𝗽𝗶𝗰 𝗰𝗵𝗮𝗻𝗴𝗲𝘀 before cell death • Go beyond cell count with multi-dimensional readouts • Use AI to classify single-cell states and predict toxic mechanisms • Fast, scalable, and cost-effective for high-throughput workflows Whether you're screening thousands of compounds or building custom disease models, this approach helps you 𝗱𝗲-𝗿𝗶𝘀𝗸 𝗲𝗮𝗿𝗹𝗶𝗲𝗿 and smarter. Dive into the full poster: https://hubs.ly/Q03v_yQg0 #CellPainting #Toxicology #DrugDiscovery #PhenotypicProfiling #SafetyScreening #ToxScreening
-
-
Join us for an exclusive BioSpace webinar featuring experts from Evotec and BioSpace as they unpack 𝘁𝗵𝗲 𝗯𝗶𝗴𝗴𝗲𝘀𝘁 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗳𝗮𝗰𝗶𝗻𝗴 𝗥&𝗗 today - and share actionable strategies to overcome them. From 𝘀𝗺𝗮𝗿𝘁𝗲𝗿 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗺𝗼𝗱𝗲𝗹𝘀 𝘁𝗼 𝘁𝗲𝗰𝗵-𝗲𝗻𝗮𝗯𝗹𝗲𝗱 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝗶𝗲𝘀, this conversation will spotlight how the industry can adapt and thrive. Whether you're in biotech, pharma, or life sciences, this is a timely conversation you won’t want to miss. With live Q&A throughout the session - join the discussion. Register now: https://hubs.ly/Q03v_BzW0 #Pharma #Biotech #LifeSciences #DrugDevelopment #PharmaInnovation
-
-
Congratulations to Rinri Therapeutics on reaching this major milestone — MHRA approval for the first-in-human trial of Rincell-1, a first-in-class regenerative cell therapy for sensorineural hearing loss! This is a significant step forward for patients affected by this condition, which deserves urgent attention given the high unmet medical need. We’re proud to have contributed to this journey. We were thrilled to support the in vivo preclinical safety package for this pioneering cell-based therapeutic. This achievement reflects the dedication of our safety scientists and the strong, collaborative spirit shared with the fantastic Rinri team. We know that no two cell therapy programs are the same. Each one requires a bespoke approach, with study designs carefully tailored to the therapy’s unique biology, route of administration and regulatory expectations. That’s why every project we support is truly one of a kind — and this one has been especially meaningful. Kudos to the entire Rinri team, and to CEO Simon Chandler, for the vision and commitment that brought this breakthrough to life. #RegenerativeMedicine #CellTherapy #HearingLoss #TranslationalScience #PreclinicalDevelopment #FirstInHuman #LifeSciences https://lnkd.in/daS5B7WN
🆕 Great news for Rinri Therapeutics & the #hearingloss community! Our first-in-human trial with regenerative cell therapy Rincell-1 has the go-ahead from the UK Medicines and Healthcare products Regulatory Agency. *️⃣ There are no disease modifying treatments for sensorineural hearing loss so Rincell-1 is addressing a multi $billion market. *️⃣ CMO/Chief Investigator Douglas Hartley on potential impact - "Working daily with individuals suffering from hearing loss, I know how devastating it can be, and the acute need for a therapy to change the disease course." *️⃣ The Trial is taking place at three UK leading hearing research centres ➡️ Open-label, 2 groups of 10 patients, randomised within each group to cochlear implantation (CI) plus Rincell-1 or CI alone ➡️ Powered to measure safety & changes in neural health, including telemetry from Advanced Bionics’ cochlear implant monitoring AIM system Find out more about the Phase I/IIa study here ➡️ https://bit.ly/3UlBdc1 #ANSD #presbycusis #celltherapy #ATMP UCB Ventures Boehringer Ingelheim Pioneer Group The University of Sheffield University of Nottingham
-